Experimental vaccine trains immune system to fight deadly brain tumor
NCT ID NCT06342908
First seen Dec 26, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-stage trial tests a custom-made vaccine for a rare and aggressive brain cancer called H3 G34-mutant diffuse hemispheric glioma. The vaccine is created from the patient's own white blood cells and designed to help the immune system recognize and attack tumor cells. The study enrolls 6 adults aged 18-50 and focuses on safety and whether the vaccine can trigger an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.